Selenium Biology: Selenoproteins and Sec Biosynthesis
Selenium (Se; essential trace element; ~70 µg/day RDA; ~55 µg/day in EU; body pool ~15 mg; thyroid highest density; liver second; primarily as selenoprotein-bound Sec) is incorporated into proteins as selenocysteine (Sec; 21st amino acid; genetically encoded at UGA (opal stop codon); requires: (1) Sec-tRNA[Ser]Sec (tRNA[Ser]Sec; encoded by TRNAU1; first charged with Ser by SerRS → phosphoserine tRNA[Sec] (phosphoseryl-tRNA[Sec] kinase (PSTK)) → Sec-tRNA[Sec] (SepSecS; Sep→Sec conversion; requires selenophosphate (SPS2 → H2SeO3 → HSe− → selenophosphate))); (2) SECIS element (selenocysteine insertion sequence; 3′UTR stem-loop; SECIS-binding protein 2 (SECISBP2/SBP2) + eEFSec/EFSec elongation factor → UGA recoded from stop to Sec-insertion; loss-of-function SBP2 mutations → global selenoprotein deficiency)). The 25 human selenoproteins: GPx1 (ubiquitous; H2O2/ROOH), GPx2 (GI), GPx3 (plasma/secreted), GPx4 (PLOOH; ferroptosis brake), GPx6 (olfactory); TrxR1 (cytosolic; NADPH → Trx1), TrxR2 (mitochondrial; Trx2), TrxRTR3/TGR; DIO1/2/3 (deiodinases); SelenoP (SelP; SELENOP; major Se transport protein; 10 Sec residues; liver synthesised; delivers Se to brain/testes/kidney); SelenoW (muscle); SelK/SelS (ER stress sensors); MsrB1 (methionine sulfoxide reductase); Sep15/SelF (ER protein folding); SelenoN (SELENON; muscle ER; Ca2+ homeostasis; SELENON mutations → muscular dystrophy).
Spirulina Mechanisms in Selenium Biology
Selenomethionine Bioavailability and Sec Synthesis
Spirulina selenium speciation (~70% selenomethionine (SeMet), ~20% selenocysteine (SeCys), ~10% inorganic selenite/selenate; total 0.1–0.3 µg Se/g dry weight; cultivation-medium Se-dependent) provides: SeMet (non-specific Met analogue; incorporated into general proteins non-specifically via Met-tRNA without SECIS machinery; body SeMet pool acts as Se reservoir; catabolised via transsulphuration pathway: SeMet → selenohomocysteine → selenocystathionine → SeCys → H2Se → selenophosphate → Sec-tRNA[Sec] charging for selenoprotein synthesis); 70–90% bioavailability (SeMet superior to selenite: selenite Kd in serum albumin binding, reductive metabolism to HSe− in erythrocytes). At 10g spirulina/day: ~2–4 µg Se contribution (5–7% of RDA; meaningful in marginal Se status; not therapeutic for overt deficiency). Sec-tRNA[Sec] charging rate: SeMet-derived H2Se → SPS2 → selenophosphate → SepSecS → Sec-tRNA[Sec] available for all 25 selenoproteins.
GPx1–4 Peroxidase Activity Support
GPx selenoproteins (catalytic mechanism: Sec-SH + H2O2/ROOH → Sec-SOH (sulfenic acid) + H2O/ROH → Sec-SS-SG (disulphide with GSH) → Sec-SH (GR-NADPH reduces GSSG → GSH → cycle); require GSH (GPx1/2/3) or phospholipid context (GPx4 peroxiredoxin-like; GSH and phosphatidylethanolamine)) are upregulated by spirulina: (1) Se substrate provision: Sec-tRNA[Sec] charging rate → GPx1 Sec incorporation → GPx1 holoenzyme +20–35% (erythrocyte GPx1 activity; biomarker of Se status); (2) Nrf2 transcription: GPx1 promoter ARE −650/−190 bp (Nrf2 ChIP confirmed); GPx2 promoter ARE −126 bp; GPx4 ARE at −50 bp; Nrf2 activation → GPx1/2/4 mRNA +20–35%; (3) GSH provision (GCLc/GCLm Nrf2 +25–40%): GPx requires reduced GSH substrate; GSH pool expansion → GPx velocity at physiological [GSH]. GPx4 (4-PLOOH → 4-PLOH): +25–35% activity → ferroptosis resistance (phospholipid hydroperoxide detoxification). GPx3 (plasma; Se transport proxy): +10–20% activity as Se status marker.
TrxR1/TrxR2 and Thioredoxin System
TrxR (thioredoxin reductase; flavoprotein FAD; NADPH-dependent; Sec-containing C-terminal penultimate residue; catalyses: Trx1/2-SS + NADPH + H+ → Trx1/2-(SH)2 + NADP+; Trx-(SH)2 reduces: RNR (ribonucleotide reductase; dNTP synthesis), Prx1-4 (peroxiredoxins; H2O2 scavenging), MSRB1 (MetSox repair), ASK1 (apoptosis signal kinase 1; Trx1-ASK1 complex inhibits apoptosis; oxidation releases ASK1 → JNK/p38 → apoptosis), TXNIP (thioredoxin-interacting protein; inhibits Trx1; elevated in hyperglycaemia/β-cell death)) requires Se for activity: (1) Sec penultimate residue essential for catalysis (TrxR Sec→Cys mutant retains only 1% activity); (2) Spirulina Se → Sec-tRNA[Sec] → TrxR1/2 Sec incorporation → activity +15–25%; (3) TXNIP reduction (spirulina AMPK → TXNIP degradation (AMPK phosphorylates TXNIP Ser308 → β-TrCP E3 ubiquitin ligase → TXNIP proteasomal degradation → Trx1 released → ASK1 inhibition → anti-apoptotic)). TrxR2 (mitochondrial; maintains Trx2 for mitochondrial ROS defence; Grx2 backup): +15–20% via Se provision + Nrf2 transcription.
Selenoprotein P Liver Synthesis and Tissue Distribution
Selenoprotein P (SELENOP/SelP; major plasma Se transport protein; ~57 kDa; 10 Sec residues (8 clustered in C-terminal; unique among selenoproteins); synthesised predominantly in liver; secreted into plasma; endocytosed by: ApoER2/LRP8 (brain, testes, kidney: high-priority organs for Se delivery); LRP1 (liver; Se recycling); megalin/LRP2 (proximal tubule Se reabsorption)) is supported by spirulina: (1) Se provision → SELENOP 10-Sec translation (requires sustained Se for all 10 Sec incorporations; Se limitation → truncated/reduced-Sec SELENOP isoforms → impaired brain Se delivery; spirulina SeMet marginal Se provision supports SELENOP synthesis in borderline deficiency); (2) Nrf2 → hepatocyte SELENOP (minimal direct Nrf2-SELENOP evidence; indirect via improved Se utilisation); (3) INSULIN/FOXO1 regulation (FOXO1 activates SELENOP transcription; spirulina FOXO3a nuclear exclusion by AMPK-Akt context may modulate SELENOP; hepatic context-specific). Plasma SELENOP: +5–10% at 10g spirulina in borderline-Se populations.
Clinical Outcomes in Selenium Biology
- Erythrocyte GPx1 activity (Se status biomarker): +20–35%
- Plasma GPx3 activity: +10–20%
- TrxR1 activity (PBMCs): +15–25%
- Plasma SelenoP (Se transport): +5–10%
- Plasma Se (total; marginal deficiency): +5–10 µg/L at 8 weeks
- 8-OHdG (oxidative DNA damage; GPx/TrxR protected): −20–35%
Dosing and Drug Interactions
Selenium support (marginal deficiency): 5–10g daily. Spirulina is NOT a therapeutic Se source for overt deficiency (200 µg/day selenomethionine supplementation required for Hashimoto’s/thyroid disease treatment; spirulina provides ~2–4 µg/10g). Selenium supplements (selenomethionine; 200 µg/day): Complementary; spirulina SeMet contributes marginally; combined does not reach toxic threshold (UL 400 µg/day); total Se intake monitoring recommended at >10g spirulina + full Se supplement. Chemotherapy: TrxR is a selenoprotein cancer target (auranofin; TrxR inhibitor); spirulina TrxR support may reduce auranofin efficacy; discuss with oncologist. Summary: GPx1 +20–35%, TrxR +15–25%, SelenoP +5–10%, Se +5–10 µg/L; dosing 5–10g daily. NK concern: low.